Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 30 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 30 samples: 11 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesisThe EMBO journal · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE276074_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1154630 and SRA study SRP526087. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 26 samples.
How we read this: 11 replicated groups read from 30 sample titles; they account for 26 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8455523 HS-SY-II Cas9 cellline cultured in vitro for 0 days, replicate1 HS-SY-II Cas9 cellline …
- GSM8455524 HS-SY-II Cas9 cellline cultured in vitro for 0 days, replicate2 HS-SY-II Cas9 cellline …
- GSM8455525 HS-SY-II Cas9 cellline cultured in vitro for 14 days, replicate1 HS-SY-II Cas9 cellline …
- GSM8455526 HS-SY-II Cas9 cellline cultured in vitro for 14 days, replicate2 HS-SY-II Cas9 cellline …
- GSM8455527 HS-SY-II Cas9 cellline in vivo in mouse (CDX), replicate1 HS-SY-II Cas9 cellline …
- GSM8455528 HS-SY-II Cas9 cellline in vivo in mouse (CDX), replicate2 HS-SY-II Cas9 cellline …
- GSM8490556 SYO-1, H2AK119ub ChIP-seq, DMSO Treated, Rep1 SYO-1, H2AK119ub ChIP-s…
- GSM8490557 SYO-1, H2AK119ub ChIP-seq, DMSO Treated, Rep2 SYO-1, H2AK119ub ChIP-s…
- GSM8490558 SYO-1, DMSO Treated, Input
- GSM8490559 SYO-1, H2AK119ub ChIP-seq, TAK-981 Treated, Rep1 SYO-1, H2AK119ub ChIP-s…
- GSM8490560 SYO-1, H2AK119ub ChIP-seq, TAK-981 Treated, Rep2 SYO-1, H2AK119ub ChIP-s…
- GSM8490561 SYO-1, TAK-981 Treated, Input
- GSM8490597 SYO-1, SS18-SSX Fusion CUT&RUN, DMSO Treated, Rep1 SYO-1, SS18-SSX Fusion …
- GSM8490598 SYO-1, SS18-SSX Fusion CUT&RUN, DMSO Treated, Rep2 SYO-1, SS18-SSX Fusion …
- GSM8490599 SYO-1, SS18-SSX Fusion CUT&RUN, DMSO Treated, Input
- GSM8490600 SYO-1, SS18-SSX Fusion CUT&RUN, TAK-981 Treated, Rep1 SYO-1, SS18-SSX Fusion …
- GSM8490601 SYO-1, SS18-SSX Fusion CUT&RUN, TAK-981 Treated, Rep2 SYO-1, SS18-SSX Fusion …
- GSM8490602 SYO-1, SS18-SSX Fusion CUT&RUN, TAK-981 Treated, Input
- GSM8490603 HS-SY-II cellline treated with DMSO, replicate1 HS-SY-II cellline treat…
- GSM8490604 HS-SY-II cellline treated with DMSO, replicate2 HS-SY-II cellline treat…
- GSM8490605 HS-SY-II cellline treated with DMSO, replicate3 HS-SY-II cellline treat…
- GSM8490606 HS-SY-II cellline treated with 25nM TAK-981, replicate1 HS-SY-II cellline treat…
- GSM8490607 HS-SY-II cellline treated with 25nM TAK-981, replicate2 HS-SY-II cellline treat…
- GSM8490608 HS-SY-II cellline treated with 25nM TAK-981, replicate3 HS-SY-II cellline treat…
- GSM8490609 SYO-1 cellline treated with 100nM TAK-981, replicate1 SYO-1 cellline treated …
- GSM8490610 SYO-1 cellline treated with 100nM TAK-981, replicate2 SYO-1 cellline treated …
- GSM8490611 SYO-1 cellline treated with DMSO, replicate1 SYO-1 cellline treated …
- GSM8490612 SYO-1 cellline treated with DMSO, replicate2 SYO-1 cellline treated …
- GSM8490613 SYO-1 cellline treated with DMSO, replicate3 SYO-1 cellline treated …
- GSM8490614 SYO-1 cellline treated with DMSO, replicate4 SYO-1 cellline treated …
- GSE276073 Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis [RNA-seq] 12 samples shares sumo2, ss18, ssx, sarcomagenesis, oncoproteins, epigenetic, targeting, reverses
- GSE276071 Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis [CUT&RUN] 6 samples shares sumo2, ss18, ssx, sarcomagenesis, oncoproteins, epigenetic, targeting, reverses
- GSE276068 Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis [ChIP-seq] 6 samples shares sumo2, ss18, ssx, sarcomagenesis, oncoproteins, epigenetic, targeting, reverses
- GSE266060 Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma [BR_ChIP-seq] 11 samples shares ss18, ssx, targeting
- GSE266199 Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma [HSH3_ChIP-seq_HS-SY-II] 9 samples shares ss18, ssx, targeting
- GSE266203 Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma [RNA-seq_HS-SY-II] 8 samples shares ss18, ssx, targeting
- GSE266064 Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma [HSJHD_ChIP-seq] 7 samples shares ss18, ssx, targeting
- GSE266063 Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma [HS18_ChIP-seq] 7 samples shares ss18, ssx, targeting
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.